AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22777094 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A/H5N1 influenza vaccine booster dose
Number of subjects: 0
Study 22777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted group (received interim booster dose at year 5)
Number of subjects: 44
Study 22777097 — intervention group
Group type: COMPARATOR
Intervention: Unboosted group (did not receive interim booster dose)
Number of subjects: 44
Study 22777097 — intervention group
Group type: COMPARATOR
Intervention: Unboosted group (after HBV vaccine challenge dose at year 20)
Number of subjects: 44
Study 22777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted group (after HBV vaccine challenge dose at year 20)
Number of subjects: 44
Study 22777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Post administration of the challenge dose
Number of subjects: 44
Study 22777131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury
Number of subjects: 126
Study 22777131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (55 mg/kg/d)
Number of subjects: 126
Study 22777131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam treatment group
Number of subjects: 126
Study 22777131 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 126
Study 22777131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam treatment
Number of subjects: 126
Study 22777623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg or 10 mg once daily for 24 weeks
Number of subjects: 12
Study 22780885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily
Number of subjects: 12
Study 22780885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium supplementation
Number of subjects: 12
Study 22780919 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-engineered T cells targeting EGFRvIII
Number of subjects: 0
Study 22781225 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells from cases (HIV-infected women)
Number of subjects: 60
Study 22781225 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-2-activated NK cells from cases
Number of subjects: 60
Study 22781225 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells from cases
Number of subjects: 60
Study 22781225 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell responses to autologous HIV-infected cells
Number of subjects: 60
Study 22782568 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-CVW
Number of subjects: 17
Study 22782568 — intervention group
Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 17
Study 22782731 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use
Number of subjects: 24471
Study 22782731 — intervention group
Group type: COMPARATOR
Intervention: No proton pump inhibitor use
Number of subjects: 24471
Study 22782731 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor use (self controlled case series)
Number of subjects: 24471
Study 22782731 — intervention group
Group type: EXPERIMENTAL
Intervention: Other 2C19 inhibitors/non-inhibitors (self controlled case series)
Number of subjects: 24471
Study 22783896 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF concentrations of amyloid-beta (Aβ)(42)
Number of subjects: 128
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ deposition measured by positron-emission tomography
Number of subjects: 128
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF concentrations of tau protein and brain atrophy
Number of subjects: 128
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hypometabolism and impaired episodic memory
Number of subjects: 128
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognitive impairment measured by Mini-Mental State Examination and Clinical Dementia Rating scale
Number of subjects: 128
Study 22784036 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for dementia
Number of subjects: 128
Study 22784116 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 38
Study 22785351 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB network therapies, specific details not available
Number of subjects: 0
Study 22786687 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21107
Study 22786877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 45
Study 22787016 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIO-labeled cells
Number of subjects: 1
Study 22788989 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy)
Number of subjects: 37
Study 22789058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte transplantation
Number of subjects: 0
Study 22789058 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 0
Study 22789619 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin E, Glutathione, Uric Acid, Total Antioxidant Capacity)
Number of subjects: 15
Study 22789619 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Uric Acid)
Number of subjects: 15
Study 22789619 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin E)
Number of subjects: 15
Study 22789619 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Antioxidant Capacity (TEAC)
Number of subjects: 15
Study 22789807 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre intake
Number of subjects: 0
Study 22789807 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate, sucrose, and fructose intakes
Number of subjects: 0
Study 22789807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase fibre intake while restricting refined sugar
Number of subjects: 0
Study 22789807 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary recommendations for children
Number of subjects: 0
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque burden
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: cIMT
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: AAD
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI
Number of subjects: 6101
Study 22789936 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery calcium score (CACS)
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaques
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 6101
Study 22789936 — intervention group
Group type: EXPERIMENTAL
Intervention: AAD >20 mm
Number of subjects: 6101
Study 22790549 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning serum melatonin levels in patients with MDD
Number of subjects: 0
Study 22790549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal serum melatonin levels in patients with MDD
Number of subjects: 0
Study 22790549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal serum melatonin levels in depressed women
Number of subjects: 0
Study 22790832 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in genetic counseling for BRCA1/2 mutations
Number of subjects: 135
Study 22790832 — intervention group
Group type: COMPARATOR
Intervention: Declined pre-test counseling
Number of subjects: 135
Study 22790881 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 440
Study 22790881 — intervention group
Group type: COMPARATOR
Intervention: Living with spouse and/or children
Number of subjects: 440
Study 22791040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar discectomy at various academic spine centers
Number of subjects: 792
Study 22792000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (50-250 mg bid)
Number of subjects: 195
Study 22792000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release and immediate release (50 mg ≤twice/day; ≥4 hours apart)
Number of subjects: 195
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization lumpectomy under stereotactic guidance
Number of subjects: 305
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of in situ disease
Number of subjects: 305
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: High tumor grade
Number of subjects: 305
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger tumor size
Number of subjects: 305
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal disease
Number of subjects: 305
Study 22794705 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mammographic microcalcifications
Number of subjects: 305
Study 22794786 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral gene therapy
Number of subjects: 0
Study 22794786 — intervention group
Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study 22795276 — intervention group
Group type: EXPERIMENTAL
Intervention: CP stent
Number of subjects: 105
Study 22795984 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet walking program and pedometer
Number of subjects: 27
Study 22796509 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 10
Study 22796509 — intervention group
Group type: EXPERIMENTAL
Intervention: dGEMRIC scan
Number of subjects: 10
Study 22797701 — intervention group
Group type: EXPERIMENTAL
Intervention: Open mesh or sutured repair for small umbilical or epigastric hernias
Number of subjects: 132
Study 22798017 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sTREM-1 levels
Number of subjects: 160
Study 22798017 — intervention group
Group type: EXPERIMENTAL
Intervention: TREM-1 SNP rs2234237
Number of subjects: 160
Study 22798017 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 160
Study 22798253 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control treatment (n=92)
Number of subjects: 437
Study 22798253 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 4 KKW (n=151)
Number of subjects: 437
Study 22798253 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 8 KKW (n=99)
Number of subjects: 437
Study 22798253 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (50% of VO(2peak)) 12 KKW (n=95)
Number of subjects: 437
Study 22800647 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0
Study 22800647 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 22800719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 2854
Study 22800719 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 2854
Study 22801008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mucosa temperature
Number of subjects: 35
Study 22801008 — intervention group
Group type: COMPARATOR
Intervention: Nasal obstruction
Number of subjects: 35
Study 22801061 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Blatchford score (GBS)
Number of subjects: 831
Study 22801061 — intervention group
Group type: EXPERIMENTAL
Intervention: age-extended GBS (EGBS)
Number of subjects: 831
Study 22801061 — intervention group
Group type: COMPARATOR
Intervention: Rockall score
Number of subjects: 831
Study 22801061 — intervention group
Group type: COMPARATOR
Intervention: Baylor bleeding score
Number of subjects: 831
Study 22801061 — intervention group
Group type: COMPARATOR
Intervention: Cedars-Sinai Medical Center predictive index
Number of subjects: 831
Study 22801963 — intervention group
Group type: EXPERIMENTAL
Intervention: GCLAC (clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Number of subjects: 0
Study 22801963 — intervention group
Group type: COMPARATOR
Intervention: FA (fludarabine and cytarabine) and FLAG (fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Number of subjects: 0
Study 22802929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 AS03-adjuvanted pandemic vaccine
Number of subjects: 13887
Study 22802929 — intervention group
Group type: COMPARATOR
Intervention: Seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 13887
Study 22803961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified risk factor management
Number of subjects: 41
Study 22804876 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 74
Study 22805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuerzburg bleb classification score ≥ 8 points
Number of subjects: 57
Study 22805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuerzburg bleb classification score ≥ 7 points
Number of subjects: 57
Study 22805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of microcysts on the filtering bleb
Number of subjects: 57
Study 22805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Target pressure (≤ 21mmHg)
Number of subjects: 57
Study 22805291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily (recommended phase 2 dose)
Number of subjects: 206
Study 22805291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 3 mg once daily (maximum tolerated dose)
Number of subjects: 206
Study 22805291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily
Number of subjects: 206
Study 22805291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 206
Study 22805292 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (oral MEK inhibitor)
Number of subjects: 97
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO(50)
Number of subjects: 36
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: J(NO)
Number of subjects: 36
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: C(alv)
Number of subjects: 36
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor allergens sensitivity
Number of subjects: 36
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: C(alv) levels
Number of subjects: 36
Study 22805466 — intervention group
Group type: EXPERIMENTAL
Intervention: J(NO) levels
Number of subjects: 36
Study 22805548 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic impedance and oximetry in a multi-modal ECG Holter system
Number of subjects: 0
Study 22805550 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Galactosidase A (aGAL A) activity measured using a dried bloodspot test (DBS) and mutation analysis of the GLA gene in males; mutation analysis as primary screening tool in females.
Number of subjects: 540
Study 22805550 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Fabry disease (FD) in patients with arterial hypertension (AHT) or LVH.
Number of subjects: 540
Study 22805651 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scan in asymptomatic FDRs
Number of subjects: 57
Study 22805651 — intervention group
Group type: COMPARATOR
Intervention: Control group (616 individuals with no family history of cardiovascular disease)
Number of subjects: 57
Study 22808058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-25 levels
Number of subjects: 405
Study 22809118 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1
Number of subjects: 144
Study 22809118 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 144
Study 22809118 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 144
Study 22809908 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic automated advisory vital signs monitors (intervention)
Number of subjects: 18605
Study 22810810 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting members of the lysyl oxidase (LOX) family of proteins
Number of subjects: 0
Study 22811928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 120
Study 22811928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22812667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subretinal injection in a clinical gene therapy trial
Number of subjects: 3
Study 22812719 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 31
Study 22812719 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 31
Study 22813439 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI) test with esomeprazole (40 mg once daily for 2 weeks)
Number of subjects: 308
Study 22813607 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum S100B levels at all time points and neuron-specific enolase levels on days 1 and 3
Number of subjects: 195
Study 22813607 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission S100B level
Number of subjects: 195
Study 22813607 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 3 S100B level
Number of subjects: 195
Study 22813607 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biomarker data
Number of subjects: 195
Study 22813874 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target core temperature of 32-34°C, cooling duration of 12-72 hours)
Number of subjects: 372
Study 22813874 — intervention group
Group type: EXPERIMENTAL
Intervention: Collapse-to-ROSC interval ≤16 min
Number of subjects: 372
Study 22814783 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious infection
Number of subjects: 5745
Study 22814783 — intervention group
Group type: COMPARATOR
Intervention: No serious infection
Number of subjects: 5745
Study 22815471 — intervention group
Group type: EXPERIMENTAL
Intervention: FASY (Women Taking Action For Their Health) intervention
Number of subjects: 200
Study 22815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² and irinotecan 75 mg/m² weekly times four on a six week cycle (Cohort I)
Number of subjects: 31
Study 22815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 750 mg/m² and irinotecan 75 mg/m² weekly times three on a four week cycle (Cohort II)
Number of subjects: 31
Study 22815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts combined
Number of subjects: 31
Study 22815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort II
Number of subjects: 31
Study 22815703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort I
Number of subjects: 31
Study 22816487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m(2) daily for 5 days every 4 weeks
Number of subjects: 37
Study 22816487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m(2)
Number of subjects: 37
Study 22816487 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 37
Study 22817698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 intravenously every 3 weeks for 6 cycles
Number of subjects: 20
Study 22817698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment
Number of subjects: 20
Study 22817798 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral overtube-assisted ERCP
Number of subjects: 0
Study 22818076 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation followed by conventional ablation (n = 36)
Number of subjects: 92
Study 22818076 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation alone (FIRM-blinded) (n = 71)
Number of subjects: 92
Study 22818076 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 92
Study 22818076 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided cases
Number of subjects: 92
Study 22818076 — intervention group
Group type: COMPARATOR
Intervention: FIRM-blinded cases
Number of subjects: 92
Study 22818801 — intervention group
Group type: EXPERIMENTAL
Intervention: iVue SD-OCT measurements in supine position
Number of subjects: 30
Study 22818801 — intervention group
Group type: EXPERIMENTAL
Intervention: iVue SD-OCT measurements in sitting position
Number of subjects: 30
Study 22818904 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose verteporfin photodynamic therapy (PDT)
Number of subjects: 13
Study 22819172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg per day, orally
Number of subjects: 41
Study 22821614 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 22821614 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 22821614 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov disease-simulation model projections for CAS
Number of subjects: 0
Study 22821614 — intervention group
Group type: COMPARATOR
Intervention: Markov disease-simulation model projections for CEA
Number of subjects: 0
Study 22823749 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube test (QFT-GIT)
Number of subjects: 244
Study 22823749 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 244
Study 22823749 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between TST and QFT-GIT
Number of subjects: 244
Study 22823749 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between TST and QFT-GIT for indurations ≥ 10 mm
Number of subjects: 244
Study 22823749 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of TB in patients with positive QFT-GIT outcomes
Number of subjects: 244
Study 22823749 — intervention group
Group type: COMPARATOR
Intervention: Incidence of TB in patients with positive TST (≥ 5 mm) results
Number of subjects: 244
Study 22824161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior superior cavopulmonary connection
Number of subjects: 546
Study 22824161 — intervention group
Group type: COMPARATOR
Intervention: No prior superior cavopulmonary connection
Number of subjects: 546
Study 22824161 — intervention group
Group type: EXPERIMENTAL
Intervention: Different superior cavopulmonary connection techniques (bidirectional cavopulmonary anastomosis, bilateral bidirectional cavopulmonary anastomosis, hemi-Fontan)
Number of subjects: 546